Results 111 to 120 of about 73,750 (259)

A Clinically Aligned Two‐Stage Machine Learning Framework for Predicting Hungry Bone Syndrome After Parathyroidectomy

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
A clinically aligned two‐stage machine learning framework integrates preoperative and perioperative features to predict hungry bone syndrome after parathyroidectomy. Explainable risk stratification may support individualised calcium management and early intervention for high‐risk patients.
Shih‐Min Yin   +10 more
wiley   +1 more source

Parathyroid hormone enhances appetite and fails to reduce adiposity in ob/ob mice. [PDF]

open access: yesPflugers Arch
Fajol A   +6 more
europepmc   +1 more source

A Second Parathyroid Hormone? [PDF]

open access: yesBMJ, 1963
C N, CRUICKSHANK   +2 more
openaire   +2 more sources

m.10010T>C Mitochondrial Disease: A Case Report With Hypoparathyroidism and Review of the Literature

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1856-1861, August 2026.
ABSTRACT Mitochondria are essential intracellular organelles that play a critical role in cellular metabolism, including the regulation of intracellular calcium signaling. Advances in genomic sequencing have facilitated the identification of rare pathogenic mitochondrial DNA (mtDNA) genetic variants in patients with unexplained endocrine disorders.
Jacob Mohr   +5 more
wiley   +1 more source

Tacrolimus‐Associated Calcium Pyrophosphate Crystal Arthritis in a Kidney Transplant Recipient: An Underrecognized Condition

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Providers who care for renal transplant recipients should be aware of the possibility of tacrolimus‐associated CPPD in patients who present with arthritis. In the case presented, a delayed diagnosis led to the progression of symptoms and avoidable disability, underscoring the need for greater clinical awareness of this condition within the ...
Matthew Wyke   +5 more
wiley   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 334-344, August 2026.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu   +5 more
wiley   +1 more source

Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis. [PDF]

open access: yesSignal Transduct Target Ther
Fang XQ   +18 more
europepmc   +1 more source

Splenic lymphoid hyperplasia in a cat presenting with hyperammonaemia, hypercalcaemia and hypercobalaminaemia

open access: yesVeterinary Record Case Reports, Volume 14, Issue 3, August 2026.
Abstract A 5‐year‐old, male neutered, Bengal‐cross cat presented with progressive neurological signs (ataxia and torticollis). Initial haematology, serum biochemistry and electrolytes (including calcium) were unremarkable; however, ammonia was markedly elevated.
Kerry E. Rolph, Tim Scase, Owen Davies
wiley   +1 more source

Home - About - Disclaimer - Privacy